HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J Am Dent Assoc, Vol 136, No 12, 1675-1681. © 2005 American Dental Association

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MELO, M. D. Articles by OBEID, G. Search for Related Content PubMed PubMed Citation Articles by MELO, M. D. Articles by OBEID, G. Related Collections Endodontics

Strategies for prevention and early recognition

Background. Bisphosphonates, inhibitors of osteoclasts, have been shown to alleviate many of the devastating consequences associated with metastatic bone disease. However, recent reports have shown that bisphosphonates may cause osteonecrosis of the jaws. Since the publication of these initial reports, the authors have treated several patients with osteonecrosis of the jaws who had a history of receiving bisphosphonate therapy.

Methods. The authors reviewed the medical records of patients who visited their clinic between September 2003 and December 2004 and who had osteonecrosis of the jaws and a history of having received bisphosphonate therapy but no irradiation to the head and neck.

Results. Eleven patients (four female and seven male) with a mean age of 69 years were included in this report. They had received bisphosphonate therapy for a mean duration of 34 months. Radiographic data showed loss of bone density at sites of osteonecrosis, and histologic examination demonstrated necrosis of bone without evidence of metastases.

Conclusions and Clinical Implications. Further research is required for better understanding of the role of bisphosphonates in the development of osteonecrosis of the jaws. Until more is known, the authors recommend that mesures be taken to prevent osteonecrosis in those at risk, including identifying patients with a history of having received bisphosphonate therapy before they undergo dental surgery. To help identify such patients, the authors propose the use of a screening questionnaire. When feasible, physicians should consult with their patients’ general dentists or oral surgeons before patients begin bisphosphonate therapy.

Key Words: Bisphosphonates; osteonecrosis; bone disease; malignancy

This article has been cited by other articles:

				S. N. Gebara and H. Moubayed Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates Am. J. Health Syst. Pharm., September 1, 2009; 66(17): 1541 - 1547. [Abstract] [Full Text] [PDF]

				A. N. LAU and J. D. ADACHI Resolution of Osteonecrosis of the Jaw After Teriparatide [Recombinant Human PTH-(1-34)] Therapy J Rheumatol, August 1, 2009; 36(8): 1835 - 1837. [Full Text] [PDF]

				E. Terpos, O. Sezer, P. I. Croucher, R. Garcia-Sanz, M. Boccadoro, J. San Miguel, J. Ashcroft, J. Blade, M. Cavo, M. Delforge, et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network Ann. Onc., August 1, 2009; 20(8): 1303 - 1317. [Abstract] [Full Text] [PDF]

				A. A. KHAN, G. K.B. SANDOR, E. DORE, A. D. MORRISON, M. ALSAHLI, F. AMIN, E. PETERS, D. A. HANLEY, S. R. CHAUDRY, B. LENTLE, et al. Bisphosphonate Associated Osteonecrosis of the Jaw J Rheumatol, March 1, 2009; 36(3): 478 - 490. [Abstract] [Full Text] [PDF]

				A. Khan Bisphosphonate-associated osteonecrosis of the jaw Can Fam Physician, July 1, 2008; 54(7): 1019 - 1021. [Full Text] [PDF]

				S.L. Ruggiero and S.J. Drew Osteonecrosis of the Jaws and Bisphosphonate Therapy Journal of Dental Research, November 1, 2007; 86(11): 1013 - 1021. [Abstract] [Full Text] [PDF]

				M. C. Adornato, I. Morcos, and J. Rozanski The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors J Am Dent Assoc, July 1, 2007; 138(7): 971 - 977. [Abstract] [Full Text] [PDF]

				C. D Krueger, P. M West, M. Sargent, A. E Lodolce, and A S. Pickard Bisphosphonate-Induced Osteonecrosis of the Jaw Ann. Pharmacother., February 1, 2007; 41(2): 276 - 284. [Abstract] [Full Text] [PDF]

				J. B. Nase and J. B. Suzuki Osteonecrosis of the jaw and oral bisphosphonate treatment. J Am Dent Assoc, August 1, 2006; 137(8): 1115 - 1119. [Abstract] [Full Text] [PDF]

				M. Q. Lacy, A. Dispenzieri, M. A. Gertz, P. R. Greipp, K. L. Gollbach, S. R. Hayman, S. Kumar, J. A. Lust, S. V. Rajkumar, S. J. Russell, et al. Mayo Clinic Consensus Statement for the Use of Bisphosphonates in Multiple Myeloma Mayo Clin. Proc., August 1, 2006; 81(8): 1047 - 1053. [Abstract] [Full Text] [PDF]

				S.-B. Woo, J. W. Hellstein, and J. R. Kalmar Systematic Review: Bisphosphonates and Osteonecrosis of the Jaws Ann Intern Med, May 16, 2006; 144(10): 753 - 761. [Abstract] [Full Text] [PDF]

				A. J. Lasser MORE ABOUT BON J Am Dent Assoc, April 1, 2006; 137(4): 441 - 441. [Full Text] [PDF]